Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase as a modality in cancer therapy
US6040334A · kind A · utility
10Cited by
2References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 20, 1994 |
| Grant date | Mar 21, 2000 |
| Priority date | — |
| Expiry date | Oct 20, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treating various cancers, such as prostatic adenocarcinoma, with inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG Co-A), such as lovastatin, are provided. Dosing ranges, schedules and toxicities are included.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.